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Objectives: No evidence-based recommendations exist for the management of infectious bursitis. We exam-
ined epidemiology and risk factors for recurrence of septic bursitis. Specifically, we compared outcome in
patients receiving bursectomy plus short-course adjuvant antibiotic therapy (7 days) with that of patients
receiving bursectomy plus longer-course antibiotic therapy (.7 days).
Patients and methods: Retrospective study of adult patients with infectious olecranon and patellar bursitis
requiring hospitalization at Geneva University Hospital from January 1996 to March 2009.
Results: We identified 343 episodes of infectious bursitis (237 olecranon and 106 patellar). Staphylococcus
aureus predominated among the 256 cases with an identifiable pathogen (85%). Three hundred and twelve
cases (91%) were treated surgically; 142 (41%) with one-stage bursectomy and closure and 146 with two-
stage bursectomy. All received antibiotics for a median duration of 13 days with a median intravenous com-
ponent of 3 days. Cure was achieved in 293 (85%) episodes. Total duration of antibiotic therapy [odds ratio
(OR) 0.9; 95% confidence interval (95% CI) 0.8–1.1] showed no association with cure. In multivariate analysis,
only immunosuppression was linked to recurrence (OR 5.6; 95% CI 1.9–18.4). Compared with 7 days,
8–14 days of antibiotic treatment (OR 0.6; 95% CI 0.1–2.9) or .14 days of antibiotic treatment (OR 0.9;
95% CI 0.1–10.7) was equivalent, as was the intravenous component (OR 1.1; 95% CI 1.0–1.3).
Conclusions: In severe infectious bursitis requiring hospitalization, adjuvant antibiotic therapy might be limited
to 7 days in non-immunosuppressed patients.
Keywords: bursectomy, parenteral, septic bursitis
Introduction
Although primary infectious olecranon and patellar (pre- and
infrapatellar) bursitis occur frequently, there are few data con-
cerning their optimal surgical and antibiotic management. Case
reports and epidemiological1 – 6 studies date from the 1970s4 – 6
and 1980s7 – 9 and involve from a few dozen cases1 – 3,6,7,9,10 to
at most 118 cases.11 Often there is no demarcation between
infectious and non-infectious bursitis.5,12 Recommendations
remain contradictory. While some advocate outpatient treat-
ment with percutaneous needle aspiration,8,11,13 antibiotics
and immobilization,5,10 others recommend hospitalization
with surgical drainage2 or suction–irrigation.7 Some advocate
intravenous (iv) therapy for up to 4 weeks in non-operative
cases,2,5,7,13,14 others, for 2–3 days followed by oral therapy for
10 days in operative cases.10,11 Some experts distinguish
between protracted and early presentation, advocating a
longer antibiotic course for the former,8 while others specifically
recommend a longer course of parenteral therapy for the
immunocompromised.3,5,8,9,13
Given today’s dual predicament of rising antimicrobial
resistance and antibiotic cost, a review of prescription practices
is warranted for all common infections. In this study, we
examine the epidemiology of infectious bursitis requiring
hospitalization and risk factors for recurrence. With an eye to
reducing catheter-related complications,15 patient and nurse
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discomfort, and healthcare costs, we assess the feasibility of
short-term oral antibiotic therapy in conjunction with surgical
bursectomy.
Patients and methods
Setting and management of infectious bursitis
The Geneva University Hospital is a 2200 bed tertiary hospital. In 2007
there were 5374 surgical procedures performed at an orthopaedic
service with 119 acute care beds and a dedicated infectious diseases
consultant.16 One day of hospitalization at standard insurance costs
1300 CHF [where CHF stands for Confoederatio Helvetica franc (Swiss
currency); US $1130 or E725]. Typically, bursectomy is performed at
admission, with immediate closure when the wound is grossly clean or
secondarily after 2–4 days of antibiotic treatment; these interventions
are followed by daily dressing changes by specialized nurses. The decision
for open or closed bursectomy is made by the treating surgeon and is
based upon local findings. Open bursectomy is usually chosen when
the involved bursa reveals extensive purulence or frank necrosis. Empiri-
cal antibiotics are administered iv until closure or availability of a
microbial resistance panel, when a switch to oral medication is made.
The overall duration of antibiotic therapy and its iv component depend
on the treating physicians. No intrabursal antibiotics are administered.
All patients wear splints for a period of 2–3 weeks; no padding is rec-
ommended thereafter. Patients are monitored in our outpatient clinic
until removal of sutures and complete clinical cure.
Data collection
Databases from the Laboratory of Bacteriology and the Administrative
Coding Centre were retrospectively searched for olecranon and patellar
bursitis in adult hospitalized patients from January 1996 to March
2009. Forty-eight variables for each episode were assessed with infor-
mation pertaining to demographic characteristics, Charlson co-morbidity
index,17 immunosuppression, microbiology, surgical and antibiotic treat-
ment modalities and outcomes. Patients were monitored until 7 April
2009. Data sampling was approved by the hospital’s Ethics Committee
(no. 08-017R); informed consent was not required.
Inclusion criteria and definitions
The definition of infectious bursitis required the following: clinical suspi-
cion of infectious bursitis in the absence of other documented pathology;
surgical and antibiotic treatment targeting infection; and the presence of
pus upon bursectomy when performed. Immunosuppression was
defined as the presence of the following co-morbidities: diabetes
mellitus; HIV infection with CD4 count ,350/mm3; status post-
transplantation requiring prolonged immunosuppressive therapy; alco-
holism; renal failure requiring dialysis; Child–Pugh class B or C liver cirrho-
sis; and active malignancy without remission (chemotherapy either
ongoing or discontinued for palliative purposes). Advanced age and poly-
trauma were not counted as factors defining immunosuppression. Bac-
teraemia was defined as positive blood cultures yielding a known
pathogenic bacterium, where blood cultures were drawn before initiation
of antibiotic therapy. C-reactive protein (CRP) levels were recorded only
when drawn before surgical intervention and initiation of antibiotics.
Cure was defined as complete clinical and microbiological resolution of
bursitis at final follow-up. Recurrence was demonstrated by clinical
signs of infection at least 2 weeks after termination of treatment for
the first episode and isolation of the same pathogen in bursal specimens.
Exclusion criteria
Ambulatory and paediatric patients (age ,17 years) were excluded, as
were those with the following conditions: non-olecranon, non-patellar
bursitis; non-primary (recurrent) infectious bursitis; non-infectious bursi-
tis, such as crystal-induced bursitis (even if co-infection); and the pres-
ence of an orthopaedic implant adjacent to the infected bursa. Finally,
bursitis patients with concomitant infections requiring antibiotic treat-
ment were excluded, such as underlying osteomyelitis diagnosed clini-
cally, by imaging or by bone biopsy.
Statistical analyses
Group comparisons of categorical variables were performed using the
Pearson x2 test. For group comparisons of non-parametrically distributed
continuous variables we used the Wilcoxon rank sum test (comparison
of two groups) or the Kruskal–Wallis test (comparison of three groups).
Logistic regression analysis determined associations with recurrence.
Only first episodes of bursitis were included in the regression analysis. Inde-
pendent variables with a P value 0.05 in the univariate analysis were
introduced stepwise in the multivariate analysis. In line with new statistical
research data,18 we included 7–10 outcome events per predictor vari-
able. Age, CRP and the duration of total or iv antibiotic treatment were ana-
lysed as continuous and categorical variables. All variables were checked
for confounding, co-linearity and interaction, the latter by Mantel–Haens-
zel estimates. According to these criteria, the variables included in the
stepwise procedure were the following: age; CRP; Charlson score; immuno-
suppression; one-stage bursectomy; duration of iv antibiotic therapy; and
duration of total antibiotic therapy. All remained in the final model.
We assessed a possible linearity of the duration of antibiotic adminis-
tration and recurrence of infection by linear regression analysis and
standard logistic regression. This procedure was performed first with con-
tinuous and categorical variables, then repeated with quadratic and log-
arithmic (ln) transformations of these variables. Further, we investigated
the potential presence of a threshold beneath which the duration of anti-
biotic administration could be associated with enhanced recurrence risk
by graphical plotting of all recurrent cases in relation to their antibiotic
duration.
We analysed antibiotic duration variables within three strata (rather
than dichotomous variables) in order to yield more detailed results. The
cut-off values for these strata were established as follows. The middle
stratum was positioned around the median value of that variable. The
inferior and superior limits were chosen according to threshold values of
a potentially increased recurrence risk. If these values were not present,
the choice was made relying on the 33% and 66% percentiles of the dis-
tribution of values of that variable. Finally, the limits were rounded up to
clinically practical durations. According to this approach, the total duration
of antibiotic treatment was analysed as a continuous variable and as a
categorical variable with the following three strata: 0–7 days; 8–14
days; and .14 days. This approach was similar for the duration of parent-
eral antibiotic therapy, with the following strata: 0–2 days; 3 days; and
.3 days. P values 0.05 (all two-tailed) were considered significant.
STATA software (v. 9.0; Stata, College Station, TX, USA) was used.
Results
Patients and bursitis
A total of 343 primary patellar (n¼106) and olecranon (n¼237)
bursitis episodes in 339 patients were identified for analysis
[median age 51 years; 281 males (82%), Table 1]. The median
length of hospital stay was 8 days [interquartile range (IQR),
6–13 days]. In 88 episodes (26%), patients were substantially
immunocompromised as defined by the presence of diabetes
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mellitus (n¼39; 25 insulin dependent), active progressive meta-
static malignancy without remission (n¼12; five undergoing che-
motherapy, seven without treatment for palliative reasons), active
alcoholism (n¼10), autoimmune disease requiring steroids
(n¼18), HIV infection (n¼7; median CD4 count of 180 cells/
mm3), solid organ transplantation (n¼1) and splenectomy (n¼1).
Seventeen patients demonstrated multifactorial immunosuppres-
sion with combinations of the above conditions plus haemodialysis
(n¼1) or liver cirrhosis (n¼1). In autoimmune patients, the median
dose of steroid therapy was equivalent to 13.75 mg of prednisolone
daily (range 7.5–70 mg). Non-penetrating trauma was the most
frequent cause of bursitides (166/343; 48%), followed by unrec-
alled/unknown source in 130 cases (38%), furunculosis (n¼18), a
history of pressure on the bursa (n¼13), scratching (n¼8), insect
bite (n¼5), drug injection (n¼2) and thorn prick (n¼1). Olecranon
bursitis was linked to physical, occupation-related activity (58%
versus 42%, x2 test, P¼0.023).
Microbiology
In 87 cases, no pathogen could be isolated. Among culture-
positive infections, Staphylococcus aureus was the most frequent
pathogen (217/256; 85%), of which three were methicillin
resistant, followed by Streptococcus pyogenes (n¼16), other
streptococci (n¼15), Enterococcus faecalis (n¼4) and
coagulase-negative staphylococci (n¼2). With the exception of
one infection with Klebsiella oxytoca alone, four other Gram-
negative organisms were co-pathogens with S. aureus. Among
the 71 episodes with blood culture sampling before the introduc-
tion of antibiotics, only three (3/71, 4%) yielded the same organ-
ism as found in bursal specimens.
Antibiotic treatment
All patients received systemic antibiotics for a median total dur-
ation of 13 days; the median duration of iv antibiotic adminis-
tration was 3 days. Among parenteral antibiotics, amoxicillin/
clavulanic acid was most frequently employed (n¼146), fol-
lowed by flucloxacillin (n¼60) and clindamycin (n¼20). Of the
oral antibiotics, clindamycin was preferred (n¼119), followed
by amoxicillin/clavulanic acid (n¼100) and flucloxacillin
(n¼37). Of note, 34 episodes (34/343, 10%) were not treated
at all with iv antimicrobials, while in 31 cases, antibiotic
therapy was strictly iv. Table 2 displays patient characteristics
according to the length of antibiotic therapy.
Table 1. Characteristics of patient populations with and without recurrence of bursitis (all bursitis: n¼343)
Recurrence,
n¼50
Comparison,
P valuea
No recurrence/cure,
n¼293
Patients
female gender, n (%) 11 (22) 51 (17)
median age (years) 49 ,0.001 62
immunosuppression, n (%)b 24 (48) ,0.001 64 (22)
median Charlson score17 1 ,0.001 0
psychiatric co-morbidities, n (%) 10 (20) 52 (18)
occupation requiring physical activity, n (%) 6 (12) 0.043 61 (21)
Bursitis and origin of bursitis
olecranon bursitis, n (%) 37 (74) 200 (68)
patellar bursitis, n (%) 13 (26) 93 (32)
traumatic origin, n (%) 24 (48) 142 (48)
median interval between trauma and onset of symptoms (days) 2 3
unknown origin/spontaneous, n (%) 26 (52) 123 (42)
median CRP level before surgery (mg/L) 54.5 57.5
Surgical treatment
median interval between onset of symptoms and bursectomy (days) 3 3
one-stage closed bursectomy, n (%) 19 (38) 0.003 123 (42)
median number of surgical interventions 1 ,0.001 2
median interval until closure (days) 0 0.029 3
Antibiotic therapy
median duration of total antibiotic therapy (days) 12 14
median duration of intravenous therapy (days) 2 0.019 4
Outcomes
median length of hospital stay (days) 7 0.026 8
aOnly P values 0.05 (two-tailed) are displayed; x2 test or Wilcoxon rank sum test.
bImmunosuppression¼diabetes mellitus, steroids, transplantation, HIV infection, alcoholism, dialysis, cirrhosis (class Child–Pugh B or C), malignancy.
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Surgical treatment
All but 31 patients (9%) underwent bursectomy a median of
3 days after onset of infection. The median number of surgical
interventions was 1 and the median interval between bursectomy
and final closure was 3 days. In 142 episodes (41%), patients
underwent one-stage bursectomy with immediate closure. In
170 episodes, there were multiple surgical interventions; in 146
cases, lavage and closure followed the first bursectomy after a
median interval of 2 days, while 24 episodes required more than
two debridements. Patients undergoing one-stage bursectomy
had a significantly shorter length of hospital stay than patients
with two-stage bursectomy (6 versus 10 days, P,0.005).
Cure and recurrence of bursitis
A total of 293 episodes (85%) achieved clinical cure, with a
median follow-up of 23 months (IQR, 2.7–67 months). Recur-
rence occurred in 50 episodes (50/343, 14.6%) (Table 1) after a
median period of 25.5 days after discontinuing antibiotic
therapy. There was an increased risk of further recurrences
after the initial recurrence; while 40 patients witnessed only
one recurrence, 10 patients with a first recurrence (20%) wit-
nessed further episodes (7 patients experienced two recurrences,
2 patients experienced three recurrences and 1 patient experi-
enced four recurrences despite extensive debridement and
weeks-long antibiotic therapy). Of the 30 patients treated only
pharmacologically, 24 (80%) experienced recurrence.
Lack of threshold and linearity between duration of
antibiotic treatment and recurrence risk
There was no threshold in the duration of total antibiotic treat-
ment beneath which the recurrence risk was increased
(Figure 1). Recurrence occurred within a range of 2–60 days for
total antibiotic therapy, and 1–21 days for iv antibiotic adminis-
tration. Likewise, the association of antibiotic duration with
recurrence was not linear according to simple linear regression,
or according to regression using quadratic or logarithmic trans-
formation of antibiotic-duration variables.
Logistic regression analyses of risk factors for recurrent
bursitis
Due to differences in the crude group comparisons (Tables 1 and
2) as well as statistically significant associations with recurrence
Table 2. Patient characteristics according to antibiotic duration (all bursitis: n¼343)
7 days of antibiotic
therapy, n¼40
8–14 days of antibiotic
therapy, n¼121
15 days of antibiotic
therapy, n¼182
Group comparisons
P values (two-tailed)a
Patients
female gender, n (%) 7 (18) 17 (14) 38 (21) 0.32
age 50 years, n (%) 25 (63) 54 (45) 98 (54) 0.10
immunosuppression, n (%)b 11 (28) 26 (21) 51 (28) 0.43
median Charlson score17 0 0 0 0.57
occupation with physical
activity, n (%)
6 (30) 21 (28) 40 (31) 0.88
Bursitis and origin of bursitis
olecranon bursitis, n (%) 23 (58) 91 (75) 123 (68) 0.10
patellar bursitis, n (%) 17 (43) 30 (50) 59 (32) 0.10
traumatic origin, n (%) 25 (63) 54 (45) 87 (48) 0.14
Surgical treatment
operated 1996–2002, n (%) 14 (35) 55 (45) 76 (42) 0.19
operated 2003–2009, n (%) 26 (65) 66 (55) 75 (41) 0.19
Antibiotic therapy
oral antibiotics throughout, n (%) 6 (15) 16 (13) 12 (7) 0.16
aPearson x2 test or Kruskal–Wallis test, as appropriate.
bImmunosuppression¼diabetes mellitus, steroids, transplantation, HIV infection, alcoholism, dialysis, cirrhosis (class Child–Pugh B or C), malignancy.
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in univariate analysis (Table 3), a multivariate analysis was per-
formed in order to adjust for case mix. ‘No surgical intervention’
was strongly related to recurrence in univariate analysis [odds
ratio (OR) 50; 95% confidence interval (95% CI) 19–135].
Because this factor was present in only a small minority of
patients, it was excluded from the multivariate model. The
final model goodness-of-fit test was 0.994, with an area under
the ROC curve of 0.835 (where ROC stands for receiver operating
characteristic).
In multivariate analysis, only the presence of immunosup-
pression could be linked to recurrence (OR 5.6; 95% CI
1.9–18.4). Neither the total duration of antibiotic treatment
(OR 0.9; 95% CI 0.8–1.1) nor its parenteral component (OR 1.1;
95% CI 1.0–1.3) was significantly associated with recurrence.
Compared with 7 days, 8–14 days of treatment (OR 0.6;
95% CI 0.1–2.9) or .14 days of treatment (OR 0.9; 95% CI
0.1–10.7) was equivalent. While the one-stage approach
yielded a trend toward a higher recurrence rate (OR 3.5; 95%
CI 0.6–21.0), this was not statistically significant.
Because immunosuppression was revealed to be significant,
we stratified the regression analysis accordingly. In both strata
(immunosuppressed and immunocompetent), no single surgical
or antibiotic-related variable was statistically associated with
recurrence. In immunosuppressed episodes, the CIs were wide,
representing possible under-powering for this stratum: age (OR
1.0, 95% CI 0.9–1.0); time interval between bursectomy and
closure (OR 1.0, 95% CI 0.8–1.1); one-stage bursectomy (OR
1.4, 95% CI 0.2–12.1); total duration of antibiotic treatment
(OR 0.9, 95% CI 0.8–1.1); or iv treatment for .3 days (OR 0.8,
95% CI 0.2–3.5).
Table 3. Predictors for recurrence of bursitis (logistic regression)
Univariate analysis
Multivariate analysis (only variables
included in the final model)
OR (95% CI) P valuea OR (95% CI) P valuea
Female gender 1.3 (0.6–2.8)
Age 1.03 (1.01–1.05) ,0.001 1.0 (1.0–1.1)
Charlson score17 1.5 (1.3–1.9) ,0.001 1.5 (1.0–2.1)
Immunosuppressionb 3.3 (1.8–6.1) 5.6 (1.9–18.4)
steroid medication 1.1 (1.0–1.2)
Occupation requiring physical activity 0.4 (0.2–1.0)
Psychiatric co-morbidities 1.3 (0.6–2.8)
Olecranon bursitis 1.3 (0.7–2.6)
Left side involvement 1.7 (0.9–3.1)
CRP before surgery 1.0 (1.0–1.0)
Bursitis due to Staphylococcus aureus 0.8 (0.4–1.4)
Traumatic origin 1.0 (0.5–1.8)
Number of surgical interventions 0.1 (0.1–0.2) 0.000
one-stage bursectomy with closure 3.6 (1.5–8.8) 0.005 3.5 (0.6–21.0)
Interval between onset of symptoms and surgery 1.0 (1.0–1.0)
Interval between first and second surgery 0.9 (0.8–1.0)
Interval between bursectomy and closure 0.9 (0.8–1.0)
Total duration of total antibiotic therapy 1.0 (1.0–1.0) 0.9 (0.8–1.1)
8–14 days compared with 7 days 0.4 (0.1–1.0) 0.6 (0.1–2.9)
.14 days compared with 7 days 0.7 (0.3–1.5) 0.9 (0.1–10.7)
Total duration of intravenous therapy 0.9 (0.8–1.1) 1.1 (1.0–1.3)
3 days compared with 2 days 0.4 (0.1–1.4) 0.4 (0.1–3.9)
.3 days compared with 2 days 0.7 (0.4–1.4) 0.7 (0.1–1.5)
Variables not included in the final model do not appear in the multivariate analysis column.
aOnly significant P values 0.05 (two-tailed) are displayed.
bImmunosuppression¼diabetes mellitus, steroids, transplantation, HIV infection, alcoholism, dialysis, cirrhosis (class Child–Pugh B or C), malignancy.
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Discussion
Recurrence of septic olecranon and patellar infectious bursitis is
common among severe illnesses requiring hospitalization. While
univariate analyses yielded several risk factors among 343 epi-
sodes, adjustment in multivariate analysis revealed only immu-
nosuppression as a risk factor for recurrence. The number of
surgical interventions, the timing of bursectomy and the interval
between first surgery and closure did not influence recurrence
risk. This was equally true for antibiotic-related parameters.
The overall duration of antibiotic therapy and the duration of
parenteral therapy or the lack thereof bore no influence on
recurrence risk. Compared with 7 days, 8–14 or .14 days of
treatment was equivalent as was the iv component. However,
the total median duration of antibiotic therapy in patients
with and without recurrence was 12 and 14 days, respectively,
while a small minority of patients were treated for 7 days.
Thus, under-powering for this particular stratum could have
been an issue. On the other hand, the relatively small CIs for
all strata argue against substantial under-powering. Moreover,
the goodness-of-fit test as well as the area under the ROC
curve were excellent, yielding a more than acceptable predictive
value for our multivariate model.
Of note, all our patients received antibiotics. Hence we were
unable to estimate recurrence rates by surgical procedures alone.
Since immunosuppression was an independent, major risk
factor, we examined whether surgical- and antibiotic-related
variables might differ when controlled and stratified based on
immune status. They did not, suggesting that immunosuppres-
sion is an independent risk factor whose mitigation is difficult
to achieve with therapy modifications. A parallel finding was
that prior recurrence itself was a strong predictor for further
recurrent episodes, suggesting a central role for endogenous
host factors. These as-yet poorly defined elements may be
only weakly influenced by medical or surgical intervention and
thus are difficult to characterize in the setting of a retrospective
study based on clinical parameters. We therefore excluded sub-
sequent recurrent episodes to avoid a massive clustering effect.
If confirmed in prospective trials, our findings could have prac-
tical implications for hospitalized patients. First, bursectomy and
closure could potentially be performed on a single-stage basis;
delayed, two-stage closure might be reserved for patients with
particularly infected or necrotic lesions and immunosuppressed
patients. We note with caution, however, that this assumption
needs confirmation by a randomized trial, as univariate analysis
and crude group comparison identified closed bursectomy as a
significant risk factor for recurrence. Statistical significance was
lost, however, once analyses were adjusted for immunosuppres-
sion and other factors.
In our setting, one-stage bursectomy led to a hospital stay
shortened by 4 days. At conservative estimates, considering
1300 CHF ($1130) per day of hospitalization and 2000 CHF
($1740) per surgical intervention, savings of at least 7000 CHF
($6100) would be achieved in each case where one-stage bur-
sectomy is performed. Secondly, in the absence of concomitant
infections, iv medication could be limited to 1–2 days or avoided
altogether (given an absence of clinical signs indicating
compromised intestinal absorption), thus reducing the risk of
catheter-related complications and costs. Third, limiting overall
antibiotic therapy to 7 days would further decrease antibiotic
consumption, cost, adverse effects and selection pressure
leading to antimicrobial resistance. This approach would be
restricted to patients undergoing surgical resection.3,7,8,11
Fourth, bursitis-related bacteraemia is extremely rare, thus
routine sampling would not be recommended in patients
without risk of secondary endovascular disease.
Our study confirms many aspects of previous reports about
septic bursitis, i.e. predominance of S. aureus followed by S. pyo-
genes,1,3,4,6,7,11 young or middle-aged male patients,1,3 – 5,11 pre-
dilection for olecranon versus patellar involvement1,19 and
trauma as the most common origin.1,2,5 In contrast, we report
a much lower incidence of positive blood cultures compared
with other reports citing rates of 19%3 and 30%.9 These higher
percentages remain somewhat debatable, as other authors
showed no episodes of bacteraemia among their 16 cases of
bursitis.6 We were not able to confirm any association between
bursitis and occupations involving pressure on the bursa.1,2,20
An infection due to S. pyogenes, the most feared pathogen of
necrotizing fasciitis,21 triggered a more aggressive initial inflam-
matory response (data not shown), yet no patient with a S. pyo-
genes infection witnessed recurrence.
Our study has its limitations. (i) It is retrospective and stems
from a single institution, aspects that limit extrapolation of its
findings. (ii) Of the 150 bursae in the human body, only olecra-
non and patellar bursitides were examined. These two are,
however, the most relevant bursae in infectious bursitis.1,10 (iii)
Recurrences may have been missed in patients who were
treated elsewhere after their initial infection. Given, however,
that Geneva University Hospital is the largest and sole public hos-
pital with the largest orthopaedic unit in the area, and the
thorough post-discharge follow-up of our patients, we consider
this selection bias to be minimal. (iv) By definition, our study
population is narrow, as we did not include milder cases of bur-
sitis requiring outpatient management with antibiotic therapy or
needle aspiration alone. Indeed, several authors contend that a
substantial proportion of patients can be managed on a purely
outpatient basis with oral antibiotics.5,10 This conservative
approach, however, harbours a treatment failure rate varying
from 9% to 32%, 48% or 51%5,11,20 and results in the pro-
longation of antibiotic therapy to a duration of up to 3 or
4 weeks,22 further complicating efforts to reduce antibiotic con-
sumption and antimicrobial resistance. (v) Lack of any surgical
intervention was the most important risk factor for recurrence
of infectious bursitis. The OR in the univariate analysis was 50
times higher in non-operated patients than in patients with at
least one surgery. Since we examined only hospitalized patients
and did not include ambulatory controls receiving conservative
treatment, we excluded lack of surgical intervention in our multi-
variate analysis in order to avoid a substantial selection bias. (vi)
It is possible that certain patients with more minor infections
both received a shorter course of antibiotics and had a more
favourable outcome simply because their bursitides were less
severe from the outset. This potential bias reinforces the need
for randomized studies.
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